Cyclophosphamide for injection USP, 500 mg, 1 g and 2 g had annual US generic sales of approximately USD332m according to IQVIA for the 12 months ending April 2018.
Amneal is focused on developing, manufacturing and distributing generic, brand, and biosimilar products.
With approximately 6,500 employees in North America, Asia, and Europe, Amneal possesses an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.
Through its Impax specialty pharmaceutical division, focused principally on central nervous system disorders and parasitic infections, the company markets branded products.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference